Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — Q3 FY25 Earnings Presentation
15 slides from Zim Laboratories's earnings presentation
Slide 1: Zim Laboratories Limited Q3 & 9M FY25 Earnings Presentation
ZIM LABORATORIES LIMITED Q3 & 9M FY25 – EARNINGS PRESENTATION
Slide 2: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 3: Content
CONTENT 01 BUSINESS MODEL 02 FINANCIAL HIGHLIGHTS 03 BUSINESS MIX 04 R&D & INNOVATION 05 SHAREHOLDING 3
Slide 4: Integrated Business Model
INTEGRATED BUSINESS MODEL Business Distinct Offerings End-to-End Product Development Verticals Across therapy segments and Dosage forms Offerings Therapy Areas Conceptualisation involves R&D Tablets Anti - Infective 01. Product Conceptualisation Export o FF and product research to examine feasibilit
Slide 5: Financial Highlights
FINANCIAL HIGHLIGHTS 9MFY25 Q3FY25 Total Operating Income stood at Total Operating Income stood at ₹963 ₹2,703 Mn, reflecting an 8.3% YoY Mn similar to that in Q3 FY24 growth from ₹2,495 Mn in 9M FY24 EBITDA grew to ₹332 Mn from ₹292 EBITDA grew to ₹133 Mn from ₹126 Mn Mn in 9MFY24, with margins in
Slide 6: Strategic & Execution Updates
STRATEGIC & EXECUTION UPDATES Innovative Products (NIP + OTF) MA & Co-Development Projects o NIP + OTF sales revenue accounted o Our Co-development partner Neuraxpharm for ₹ 477 Mn for 9MFY25, an increase received an MA for Buprenorphine of 83% YoY sublingual films across Europe o Successful CPHI ev
Slide 7: Financial Performance – 9MFY25
FINANCIAL PERFORMANCE – 9MFY25 TOTAL OPERATING INCOME EBITDA & EBITDA MARGIN PROFIT AFTER TAX (PAT) & PAT MARGIN 11.7% 12.3% 3.6% 2.7% 2, 703 332 2, 495 91 292 73 9MFY24 9MFY25 9MFY24 9MFY25 9MFY24 9MFY25 Total Operating Income (₹ Mn) EBITDA (₹ Mn) PAT (₹ Mn) o Total Operating Income grew 8.3% YoY t
Slide 8: Financial Performance – Q3FY25
FINANCIAL PERFORMANCE – Q3FY25 TOTAL OPERATING INCOME EBITDA & EBITDA MARGIN PROFIT AFTER TAX (PAT) & PAT MARGIN 13.1% 11.0% 11.8% 13.8% 5.0% 1.1% 2.6% 4.2% 963 963 133 48 922 40 126 818 109 24 90 9 Q3FY24 Q1FY25 Q2 Q3 Q3FY24 Q1FY25 Q2 Q3 Q3FY24 Q1FY25 Q2 Q3 Total Operating Income (₹ Mn) EBITDA (₹ M
Slide 9: Business Mix
BUSINESS MIX Pharma Revenue (₹ Mn) & Contribution to Total Nutra Revenue (₹ Mn) & Contribution to Total Operating Income (%) Operating Income (%) 33% 83% 77% 29% 74% 71% 26% 67% 23% 17% 978 255 266 268 224 708 739 201 654 552 Q3 Q4FY24 Q1FY25 Q2 Q3 Q3 Q4FY24 Q1FY25 Q2 Q3 o Q3 FY25: The Pharma busine
Slide 10: Revenue Mix
REVENUE MIX Q3FY24 Q3FY25 9MFY24 9MFY25 33, 3% 39, 4% 133, 5% 98, 4% 144, 15% 461, 19% 358, 13% 246, 26% 1,901, 76% 2,247, 83% 684, 71% 780, 81% Export India Deemed Export Numbers in ₹Mn o Q3 FY25: The export business grew 14% YoY to ₹780 Mn, up from ₹684 Mn in Q3 FY24, driven by demand in key marke
Slide 11: Innovative Product Contribution
INNOVATIVE PRODUCT CONTRIBUTION (NIP + OTF) Revenue (₹ Mn) & Contribution to Total Operating Income (%) 21.8% 17.8% 14.0% 12.7% 178 10.3% 164 9.5% 8.5% 135 109 112 82 70 2.5% 26 Q4FY23 Q1FY24 Q2 Q3 Q4 Q1FY25 Q2 Q3 9MFY25 revenue stands at Rs. 477 Mn, up 83% YoY o 9M FY25: Agreements for Innovative P
Slide 12: R&D Driving Product Innovation
R&D DRIVING PRODUCT INNOVATION R&D Expense Mix % of Total R&D Investment 9.1% 9.5% 85 2 76 Total R&D Investment as % of Total 32% 33% Operating Income R&D Team Post- PhDs Size Graduates 7% 3% Capital Expenses on BE study, registrations etc 6 4 ₹257 Mn Capital Expenses on Allocated Infrastructure & 6
Slide 13: Income Statement
INCOME STATEMENT Particulars (₹ Mn) Q3FY25 Q3FY24 YoY% 9MFY25 9MFY24 YoY% Total Operating Income 963 963 0.0% 2,703 2,495 8.3% Other Income 18 11 63.6% 41 36 13.9% Total Income 981 974 0.7% 2,744 2,531 8.4% EBITDA 133 126 5.6% 332 292 13.7% EBITDA % 13.8% 13.1% 70 bps 12.3% 11.7% 60 bps Profit Befor
Slide 14: Shareholding
SHAREHOLDING Ownership % (December 2024) Traded Volume (In K) BSE+NSE 40,248 13% 33% 5% 26,593 8% 15,997 13,089 14,093 11,313 41% Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Promoter HNI NRI & Foreign Individuals Body Corporates • Number of Shareholders in Q3FY25 accounted to 17.4K Other Public Shareh
Slide 15: Thank You
THANK YOU INVESTOR RELATIONS ZIM’s Investor Relations Mr. Zain Daud zain.daud@zimlab.in M: +91 9022434631 GoIndia Advisors – IR Firm Ms. Sheetal Khanduja Ms. Deepika Sharma Ms. Priya Sen sheetal@goindiaadvisors.com deepika@goindiaadvisors.com priya@goindiaadvisors.com M:+91 9769364166 M:+91 84510295